<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221018056230N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-26</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Investigation of 4% topical sucralfate in the topical treatment of children with diaper dermatitis</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of 4% Topical Sucralfate in Erosive Candidial Diaper Dermatitis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>32</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66397</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.</study_design>
      <phase>2</phase>
      <hc_freetext>Erosive Candidial Diaper Dermatitis.</hc_freetext>
      <i_freetext>Intervention group: The medicine used is 4% sucralfate gel, the medicine will be applied every 4 or 5 hours when the child is awake, 5 times a day, in the affected area in the form of a thin layer covering the skin.The drug will be administered in the Faculty of Pharmacy of Isfahan University of Medical Sciences under the supervision of a pharmacist. To prepare one hundred grams of four percent sucralfate gel, first heat 85 ml of purified water on an electric heater until it reaches the boiling temperature, and after turning off the heat source at a temperature of 80 degrees Celsius, add 180 mg of methyl paraben and 20 A milligram of propyl paraben will be added to it, and then at a temperature of 50 degrees Celsius, one gram of carbomer 934, which has already been weighed, will be added to the formula.Half an hour later, that is, when the carbomer was hydrated, the formulation was stirred for 10 minutes with the help of a glass rod, and when the temperature of the formulation reached about 25 degrees Celsius, 4 grams of sucralfate powder, which was previously dissolved in ten milliliters of water, was added. The solution is added to the base and stirred with a glass rod for ten minutes until a homogeneous formulation is obtained. If the pH of the formulation is acidic, two drops of triethanolamine will be added and stirred to neutralize it. Finally, the final formulation will be packed in soft tubes. The contents on the tube box (consumer instructions) include the following: This medicine can only be used for skin use and under the supervision of a physician. In case of any skin reaction, consult the physician.The medicine should be stored at a temperature below 25 degrees Celsius and in a dry and cool place, away from direct sunlight and out of the reach of children. After opening the medicine tube, it can be used for up to one month at room temperature. Do not leave it in the environment and close it tightly. Avoid applying the medicine in sensitive areas such as around the eyes or on the face. Sample Size and Sampling Method: The sample size required for this study was calculated using the sample size estimation formula to compare the averages mentioned below and considering the confidence level of 95%, the power of the test is 80%, the average number of times for Improvement of lesions in a similar study and taking into account the minimum significant difference between the two groups of case and control for 1 day, the number of samples required in each of the case and control groups was estimated to be 22 people, taking into account 10% sample loss. Eligible people to enter the study are randomly assigned to each of the case and control groups in a random permutation block method with a size of 4. How to use the medicine:The medicine will be applied every 4 or 5 hours when the child is awake, 5 times a day, in the affected area in the form of a completely covering thin layer on the skin. Necessary training will be given to the mother on how to use the medicine during the first visit. How to teach: The health and preventive measures that will be taught to mothers along with taking medicine are as follows: using linen diapers or washable cotton diapers that are washed and rinsed with soap, changing diapers or diapers regularly. As soon as the infant or child urinates, a complete explanation of the causes of diaper dermatitis including detergents, urine, diarrhea, the infant, the type of feeding and the type of diaper or the age of the infant. The number of training sessions: It is proportional to the visits of patients with their parents.Study grouping: In this study, patients are randomly divided into two groups with equal numbers. Both groups received standard treatment for diaper dermatitis including topical clotrimazole three times a day. In addition to being treated with clotrimazole ointment three times a day (every 8 hours), the treatment group is also treated with topical sucralfate 4% every 4 or 5 hours when the child wakes up 5 times a day..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is After the conclusion of the effectiveness of the drug, a decision is made to release it</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyedeh Zahra Moosavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit. 1, No.8, Alvan 14 Alley, Ebrahimi St, Marzdaran Blva</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1461886681</zip>
        <telephone>+98 21 4429 9733</telephone>
        <email>szm.gp68@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyedeh Zahra Moosavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit. 1, No.8, Alvan 14 Alley, Ebrahimi St, Marzdaran Blva</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1463735641</zip>
        <telephone>+98 21 4429 9733</telephone>
        <email>szm.gp68@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children less than 2 years after infancy with a new clinical diagnosis of Candidiasis Rosacea due to diaper movement</inclusion_criteria>
      <agemin>30 days</agemin>
      <agemax>2 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The medicine used is 4% sucralfate gel, the medicine will be applied every 4 or 5 hours when the child is awake, 5 times a day, in the affected area in the form of a thin layer covering the skin.The drug will be administered in the Faculty of Pharmacy of Isfahan University of Medical Sciences under the supervision of a pharmacist. To prepare one hundred grams of four percent sucralfate gel, first heat 85 ml of purified water on an electric heater until it reaches the boiling temperature, and after turning off the heat source at a temperature of 80 degrees Celsius, add 180 mg of methyl paraben and 20 A milligram of propyl paraben will be added to it, and then at a temperature of 50 degrees Celsius, one gram of carbomer 934, which has already been weighed, will be added to the formula.Half an hour later, that is, when the carbomer was hydrated, the formulation was stirred for 10 minutes with the help of a glass rod, and when the temperature of the formulation reached about 25 degrees Celsius, 4 grams of sucralfate powder, which was previously dissolved in ten milliliters of water, was added. The solution is added to the base and stirred with a glass rod for ten minutes until a homogeneous formulation is obtained. If the pH of the formulation is acidic, two drops of triethanolamine will be added and stirred to neutralize it. Finally, the final formulation will be packed in soft tubes. The contents on the tube box (consumer instructions) include the following: This medicine can only be used for skin use and under the supervision of a physician. In case of any skin reaction, consult the physician.The medicine should be stored at a temperature below 25 degrees Celsius and in a dry and cool place, away from direct sunlight and out of the reach of children. After opening the medicine tube, it can be used for up to one month at room temperature. Do not leave it in the environment and close it tightly. Avoid applying the medicine in sensitive areas such as around the eyes or on the face. Sample Size and Sampling Method: The sample size required for this study was calculated using the sample size estimation formula to compare the averages mentioned below and considering the confidence level of 95%, the power of the test is 80%, the average number of times for Improvement of lesions in a similar study and taking into account the minimum significant difference between the two groups of case and control for 1 day, the number of samples required in each of the case and control groups was estimated to be 22 people, taking into account 10% sample loss. Eligible people to enter the study are randomly assigned to each of the case and control groups in a random permutation block method with a size of 4. How to use the medicine:The medicine will be applied every 4 or 5 hours when the child is awake, 5 times a day, in the affected area in the form of a completely covering thin layer on the skin. Necessary training will be given to the mother on how to use the medicine during the first visit. How to teach: The health and preventive measures that will be taught to mothers along with taking medicine are as follows: using linen diapers or washable cotton diapers that are washed and rinsed with soap, changing diapers or diapers regularly. As soon as the infant or child urinates, a complete explanation of the causes of diaper dermatitis including detergents, urine, diarrhea, the infant, the type of feeding and the type of diaper or the age of the infant. The number of training sessions: It is proportional to the visits of patients with their parents.Study grouping: In this study, patients are randomly divided into two groups with equal numbers. Both groups received standard treatment for diaper dermatitis including topical clotrimazole three times a day. In addition to being treated with clotrimazole ointment three times a day (every 8 hours), the treatment group is also treated with topical sucralfate 4% every 4 or 5 hours when the child wakes up 5 times a day.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Diaper dermatitis severity percentage before, 3, 7 and 10 days after the intervention in case and control groups. Timepoint: First, third, seventh and tenth days. Method of measurement: Diaper Severity Score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-31</approval_date>
        <contact_name>Ethics Committees of School of Medicine - Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences, No.1, Hezar jarib Blvd, Isfahan, Islamic Republic of Iran Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
